Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

Sequential Skin Ltd, a world leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, are proud to announce that they have been awarded the prestigious UK-Singapore ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.